Clinical TrialJun 4, 2026, 07:31 AM
Rezolute to Present 4 Times at ENDO 2026, Including sunRIZE Data
AI Summary
Rezolute, Inc. announced four presentations at the upcoming Annual Meeting of the Endocrine Society (ENDO) from June 13-16, 2026. These include an oral presentation on previously reported top-line results from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism (HI), which did not meet its primary or key secondary endpoints in December 2025. Additionally, three poster presentations will cover the natural history and adverse outcomes of congenital HI, and results from the ersodetug clinical development program, including a case series on compassionate use in tumor HI patients.
Key Highlights
- Rezolute to make four presentations at the ENDO 2026 Annual Meeting from June 13-16.
- One oral presentation will highlight previously reported Phase 3 sunRIZE study results for ersodetug.
- The sunRIZE study did not meet its primary or key secondary endpoints, as announced in December 2025.
- Three poster presentations will cover congenital HI natural history and ersodetug clinical program.
- One poster details compassionate use of ersodetug in patients with malignant insulin-secreting tumors.
- Another poster discusses early-life hypoglycemia association with neurological outcomes in congenital HI.
- The FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation of the sunRIZE program.
Price Impact
More from RZLT